StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)

Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Royalty Pharma's EV/EBITDA was 33.2× on Nov 11, 2026, against 22.3× a year earlier. Over the last 5 years it ranged from 15.3× to 81.7×, with a median of 26.3×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202633.2×+11.4
2025Dec 31, 202521.7×+5.4
2024Dec 31, 202416.3×−45.4
2023Dec 29, 202361.7×+27.6
2022Dec 30, 202234.2×+14.1
2021Dec 31, 202120.1×–

More Royalty Pharma figures

See a number that looks wrong?